Akumin — Q2 2022 Earnings Presentation
13 slides from Akumin's earnings presentation, Aug 10, 2022
Slide 1: Q2 2022 Results
Akumin Inc. Q2 2022 Results August 10, 2022 Riadh Zine, Chairman & CEO Bill Larkin, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: Q2 2022 Performance Highlights
Q2 2022 Performance Highlights • Same Store Volumes on a pro forma basis across the platform continued to trend positively, except for Oncology Patient Starts: • MRI: +2.0% • PET/CT: +6.4% • Total Radiology Procedures: +4.5% • Total Oncology Patient Starts: (1.4%) • Revenue of $192.1M, up 176.5% vs.
Slide 4: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities Service Lines • Diversification of revenue (% of Revenue) 1 between Radiology and Radiology Procedure Mix (% of Revenue) Oncology divisions • Akumin provides a full suite 18% of radiology and oncology 21% services with a focus on high-growth and high- 55% value m
Slide 5: Diverse Payor Mix
Diverse Payor Mix TTM Q2’22 Pro Forma Payor Mix1 ~95% of the company’s overall (% of Revenue) revenue is derived from outpatient procedures • 51% of revenue is received via third party and government payors, and reimbursed at outpatient rates • 49% of revenue is received via health systems and hospi
Slide 6: Radiology Volume Trends
Radiology Volume Trends • Same Store MRI Volume Growth: +2.0% in Q2 2022 • Same Store PET/CT Volume Growth: +6.4% in Q2 2022 • Same Store Total Procedures Volume Growth: +4.5% in Q2 2022 Same Store Volume Growth1 MRI Procedures PET/CT Procedures Total Procedures 54.2% 20.6% 44.3% 7.1% 6.4% 8.5% 6.2%
Slide 7: Oncology Volume Trends
Oncology Volume Trends • Same Store Patient Start Volume Growth: (1.4%) in Q2 2022 • Patient Start Volume has returned to pre-pandemic (2019) levels • Revenue/Patient Start is down slightly due to mix (more Linac patient starts vs SRS) Same Store Patient Start Volume Growth1 Total – Patient Starts V
Slide 8: Segment Financial Performance
Segment Financial Performance Q2 2022 TTM Pro Forma1 as of Q2 2022 ($ in M) RAD ONC Corp Total ($ in M) RAD ONC Corp Total Revenue $ 160.9 $ 31.3 $ - $ 192.1 Revenue $ 612.6 $ 130.0 $ (0.0) $ 742.7 % vs PY - Fav(Unfav) 131.5% 176.5% % vs PY TTM - Fav(Unfav) 4.6% -0.5% 3.7% 2 2 Adjusted EBITDA $ 35.7
Slide 9: Integration and Regulatory Update
Integration and Regulatory Update • Integration Progress • Synergy Achievement: Incurred $7.4mm in restructuring charges and $5.6mm in related severance costs as part of our effort to streamline the organization and remove functional duplication. • Fixed-site consolidation: Akumin rationalized 7 fix
Slide 10: 2022 Guidance Maintained
2022 Guidance Maintained • Maintaining our full-year Revenue and Adjusted EBITDA Guidance • Positive same store volume across the Radiology platform and continued strong new customer acquisition as well as retention. • Previously disclosed synergies related to integration initiatives are expected to
Slide 11: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation for Growth Akumin’s capital structure is comprised Total Secured Debt $910.2 of a diverse set of capital providers including traditional banks, bondholders Less: Cash 38.4 and Stonepeak as debt and equity Net Secured Debt $871.8 stakeholders. Adjusted EBITDA1 $
Slide 12: Thank you!
Thank you! Riadh Zine, Chairman & CEO Bill Larkin, Chief Financial Officer
Slide 13: Appendix 1: Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
Appendix 1: Reconciliation of Net Loss to EBITDA and Adjusted EBITDA ($ in thousands) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net loss $ (26,079) $ (6,854) $ (52,511) $ (9,362) Interest expense 29,290 8,920 57,971 17,288 Income tax expense (benefit) (3,483) 6 (2,920